Chest CT Biomarkers as Prognostic Predictors in SSc-ILD
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: HRCT biomarkers.
- Who it may be relevant to
- Registry conditions: Systemic Sclerosis. Basic parameters: 18 years — 99 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France, Germany, Italy, United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Deep-learning Derived Chest Computed Tomography (CT) Biomarkers as Prognostic Predictors in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Overview
The goal of this retrospective observational study is to investigate whether novel imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline predict ILD progression, vasculopathy development, and survival in SSc-ILD.
Detailed description
Interstitial lung disease (ILD or lung fibrosis=stiffening of the lungs by scar tissue) develops in over half of patients with systemic sclerosis (SSc). Whilst ILD remains stable in some patients, at least a third have progressively increasing fibrosis. There is a pressing need for accurate indicators that identify a) patients at higher risk of progression, needing immediate treatment to prevent further irreversible ILD; and b) patients at lower risk, not needing treatment.
In this study the prognostic potential and accuracy of machine-learning derived biomarkers to evaluate abnormalities that are difficult to quantify visually will be investigated. Whether novel high resolution computed tomography (HRCT) imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline can predict ILD progression, vasculopathy development, and survival will be investigated in a cohort of approximately 1,000 SSc-ILD patients.
The algorithm scores will be evaluated against survival using Cox proportional hazards modelling, while mixed effects model analysis will be used to assess links with change in lung function: forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLco), and carbon monoxide transfer coefficient (Kco). The airway algorithm measuring traction bronchiectasis (dilatation of the airways due to surrounding fibrosis) may predict worsening of FVC, reflective of ILD progression. The vessel algorithm may predict decline in KCO, a marker of pulmonary vascular involvement. Exploratory analyses evaluating change in HRCT fibrosis extent over time for patients with repeat HRCTs will also be performed, and whether composite outcomes of change in HRCT and lung function variables improve long term outcome prediction and pave the way to their use in clinical trials and routine clinical use. Patients with trivial changes on CT will also be included to assess for very early changes that could be predictive of future decline. These algorithms will be combined with the findings of our previous study, which suggest that a certain type of pattern on CT called UIP predicts shorter survival.
Interventions
- Diagnostic test HRCT biomarkers
HRCT imaging biomarkers of airways, vessels, and overall extent of fibrosis
Primary outcome measures
- Survival [Time frame: 15 years]
- Pulmonary hypertension [Time frame: 15 years]
- Decline in FVC [Time frame: 15 years]
- Decline in DLCO [Time frame: 15 years]
- Decline in KCO [Time frame: 15 years]
Eligibility criteria
Inclusion criteria
- diagnosed with SSc
- ≥18 years old
- HRCT between 01/01/1990 and 31/12/2019
Exclusion criteria
- Patients who do not have SSc
- <18 years old
- lack of availability of HRCT imaging data
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Italy · 3 centers
- Marche Polytechnic University — Ancona
- Sassari University — Sassari
- Siena University Hospital — Siena
United Kingdom · 2 centers
- Leeds Hospital/University of Leeds — Leeds
- Royal Brompton Hospital — London
France · 1 center
- Bichat-Claude Bernard hospital — Paris
Germany · 1 center
- Hanover Medical School — Hanover
Identifiers
NCT: NCT06472362 · RBH2